Skip to content

Trial Summary

A randomised phase II trial comparing the efficacy of single-dose or fractionated SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer (AZTEC)



ACTRN/NCT /ethics:


Scientific title:

Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer

Sponsor / Cooperative group:

Peter MacCallum Cancer Centre, Australia

Trial & Patient Characteristics

Cancer TypeBreast
Trial TypeTreatment
PhasePhase II
Age Range18+ years
Tumour Stream Breast
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2018-08-01
Anticipated End Date2022-04-01

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Phone08 7074 2342
Principal InvestigatorDr Hien Le
Recruitment StatusRecruiting